Roche’s acquired GLP-1/GIP normalises blood sugar in Phase II trial

Roche drops the data for its GLP-1/GIP as the obesity and type 2 diabetes markets continue to grow exponentially. Roche drops the data for its GLP-1/GIP as the obesity and type 2 diabetes markets continue to grow exponentially. Roche has already advanced the asset to Phase III trials in chronic weight management. Credit: OleksSH / Shutterstock.com Roche’s acquired GLP-1/GIP receptor agonist, enicepatide, normalised blood sugar and reduced weight in patients with type 2 diabetes and overweight or obesity in a Phase II trial. In the CT-388-104 study (NCT06628362), enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in…

Source: Clinical Trials Arena